secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001558370-24-010958
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KALA BIO reports Q2 net loss of $9.6M, cash $54.2M; Phase 2b data due Q1 2025
-----------------------------------------------------------------------------

- Net loss of $9.6M ($3.16 per share) for Q2 2024 vs. $10.4M ($4.36 per share) a year ago.
- Cash and equivalents $54.2M at June 30, 2024; with CIRM award, runway expected into Q4 2025.
- Closed $12.5M private placement led by SR One; net proceeds of $12.3M.
- Topline results from Phase 2b CHASE trial of KPI-012 for PCED targeted in Q1 2025.
- R&D expenses rose to $5.3M from $4.3M on higher KPI-012 development costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000155837024010958/0001558370-24-010958-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000155837024010958/kala-20240806x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-010958

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer